Latest Biotechnology, Pharmaceutical and Healthcare News from PharmaTimes

00:47 EDT 21st June 2018 | BioPortfolio

Here are the most relevant search results for "PharmaTimes" found in our extensive news archives from over 250 global news sources.

More Information about PharmaTimes on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmaTimes for you to read. Along with our medical data and news we also list PharmaTimes Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaTimes Companies for you to search.

Showing News Articles 1–25 of 1,000+ from PharmaTimes

Wednesday 20th June 2018

UK announces review of medicinal cannabis

Home secretary Sajid Javid has announced a review of medicinal cannabis in the UK, in response to growing pressure to allow use of cannabis oil to help control seizures in children with severe forms of epilepsy.

Pancreatic cancer survival much lower than thought, research finds

Pancreatic Cancer UK is calling for greater investment in research funding for pancreatic cancer as new data reveals that just three percent of patients with the most common form will survive beyond five years.

Novo, Kallyope link to develop obesity, diabetes therapies

Novo Nordisk and Kallyope are joining forces to discover novel peptide therapeutics for obesity and diabetes.

Amgen’s Blincyto gets full EU approval for rare leukaemia

European regulators have awarded Amgen’s Blincyto full approval for Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow thought to affect around 900 patients a year in the region.

US approves joint damage data for Cosentyx

US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).

Tuesday 19th June 2018

Abcam appoints Peter Allen as non-executive chairman

Phase III success for Janssen’s esketamine in treatment-resistant depression

Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.

Roche snaps up rest of Foundation Medicine for $2.4bn

Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.

US regulators reject Valeant’s Duobrii

The US Food and Drug Administration has rejected Valeant group Ortho Dermatologics’ plaque psoriasis therapy Duobrii.

Scotland to house world-first manufacturing innovation centre

A £56-million drug manufacturing innovation centre - the first of its kind in the world - has been announced for Renfrewshire in Scotland.

Tax rises on the horizon for NHS budget hike

Prime Minister Theresa May has confirmed that tax rises will be necessary to help fund the planned NHS budget increase.

Monday 18th June 2018

Avacta appoints Dr Eliot Forster as non-executive chairman

GammaDelta Therapeutics appoints Michael Koslowski as CMO

AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo

AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.

Publicis Resolute promotes Emma Knott to head of social media

DDF, Immuneering form $1.3m Alzheimer’s research collaboration

Britain’s Dementia Discovery Fund has formed a research collaboration with US group Immuneering Corporation that aims to identify novel drug targets and candidates for Alzheimer's disease.

Teva pulls fremanezumab cluster headaches trial

Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.

Prime Minister reveals £20bn a year boost for NHS

By 2023/24 there will be £20 billion more a year being spent on the NHS “in real terms”, Prime Minister Theresa May has revealed.

Friday 15th June 2018

Digital therapy group Healios raises £2.2 million

UK-based digital therapy group Healios has raised £2.2 million in its latest funding round.

Rare disease therapy Crysvita to be barred from NHS

Children and young people with X-linked hypophosphataemia (XLH) are unlikely to get routine access to Kyowa Kirin’s Crysvita on the NHS.

Keytruda approved for second blood cancer

US regulators have again expanded the list of approved uses of MSD’s immunotherapy Keytruda, issuing a green light for the treatment of primary mediastinal large B-cell lymphoma (PMBCL).

NICE rejects adjuvant use of Perjeta post-surgery

The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.

Thursday 14th June 2018

Wales backs NHS use of Actelion’s Uptravi for PAH

Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).

Mental health spend must double to raise treatment levels, finds report

Spend on mental health will need to double to bring the proportion of people receiving NHS treatment up from 40 percent to 70 percent, claims a report commissioned by the NHS Confederation.

Final NICE nod for Janssen’s Tremfya

The National Institute for Health and Care Excellence (NICE) has now issued guidance recommending Janssen’s Tremfya as an option for treating plaque psoriasis in adults on the NHS.

Quick Search


News Quicklinks